TERT and non-small cell lung carcinoma: In NSCLC, 54% of subjects had a specific response after GV1001+p540+GM-CSF vaccine with improved survival (median OS 19 vs 3.5 months in TERT responders and non-responders, p < 0.001) [101,123].